Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 90100 aerosol foam in adolescents with plaque psoriasis
NL-OMON42757Phase 2Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of calcipotriol and betamethasone dipropionate in plaque psoriasis and psoriasis, sponsored by LEO Pharma. Primary endpoints: Adverse events, Abnormal ACTH challenge response at Week 4 and 3 more. Started Aug 2016; status: active, not recruiting.
02
Drugs
calcipotriolbetamethasone dipropionate
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NL-OMON42757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42757.